Key result
Levosimendan significantly improved the 30-day survival rate compared with enoximone (69% vs 37%, p=0.023) in patients with refractory cardiogenic shock complicating acute myocardial infarction.
Why the study?
Does levosimendan improve survival compared to enoximone in patients with refractory cardiogenic shock complicating acute myocardial infarction?
RCT (n=32)
randomized
No
Does levosimendan improve survival compared to enoximone in patients with refractory cardiogenic shock complicating acute myocardial infarction?
In patients with refractory cardiogenic shock complicating acute myocardial infarction, levosimendan added to standard therapy significantly improved 30-day survival compared to enoximone.
Answers are grounded in this paper and cite their sources.
Supports levosimendan over enoximone in refractory post-MI cardiogenic shock; extends RCT evidence for inotrope selection.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Fuhrmann et al. (2008) conducted an RCT in refractory cardiogenic shock complicating acute myocardial infarction (n=32). Levosimendan vs. Enoximone was evaluated on Survival rate at 30 days (p=0.023). Levosimendan significantly improved the 30-day survival rate compared with enoximone (69% vs 37%, p=0.023) in patients with refractory cardiogenic shock complicating acute myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: